AFT PharmaceuticalsNZSE:AFT 95 Gross Margin % is 42.69% as of Mar. 2026, which is 3% below its 10-year median of 44.09. GuruFocus rates NZSE:AFT with a GF Score™ of 95/100 and a GF Value™ of NZ$4.18 (Fairly Valued). The stock has 4 warning signs investors should review. Among 943 Drug Manufacturers companies, AFT Pharmaceuticals ranks worse than 60.45% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
AFT Pharmaceuticals had a gross margin of 42.69% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
AFT Pharmaceuticals Gross Margin % Related Terms
AFT Pharmaceuticals Gross Margin % Historical Data
* Premium members only.
The historical data trend for AFT Pharmaceuticals's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NZSE:AFT vs ZTS, UTHR, VTRS: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, AFT Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AFT Pharmaceuticals Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AFT Pharmaceuticals's Gross Margin % distribution charts can be found below:
* The bar in red indicates where AFT Pharmaceuticals's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
AFT Pharmaceuticals (NZSE:AFT) has a Gross Margin % of 42.69% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on AFT Pharmaceuticals and its competitors. This is near median its historical median of 44.09. Over the past decade, AFT Pharmaceuticals' Gross Margin % has ranged from 37.57 to 47.85. According to the industry distribution chart, AFT Pharmaceuticals ranks #570 out of 943 companies in the Drug Manufacturers industry, placing it in the top 60.4%.
Is AFT Pharmaceuticals' Gross Margin % too high?
AFT Pharmaceuticals' current Gross Margin % of 42.69% is near median its 10-year median of 44.09. Over the past 10 years, this metric has ranged from a low of 37.57 to a high of 47.85. The Drug Manufacturers industry median Gross Margin % is 48.54. AFT Pharmaceuticals' value of 42.69% is 12.1% below this industry median. Based on the distribution chart, AFT Pharmaceuticals ranks #570 out of 943 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, AFT Pharmaceuticals has a GF Score™ of 95/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does AFT Pharmaceuticals' Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, AFT Pharmaceuticals ranks #570 out of 943 companies for Gross Margin %. This places AFT Pharmaceuticals in the lower half of its industry. The industry median Gross Margin % is 48.54. AFT Pharmaceuticals' value of 42.69% is 12.1% below this benchmark. Historically, AFT Pharmaceuticals' own Gross Margin % has ranged from 37.57 to 47.85 over the past decade. While the company's 10-year median is 44.09 vs. the industry median of 48.54, AFT Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 943 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AFT Pharmaceuticals's current Gross Margin % of 42.69% is 12.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on AFT Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AFT Pharmaceuticals's current Gross Margin % is 42.69%, which is near median its own 10-year median of 44.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AFT Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, AFT Pharmaceuticals (NZSE:AFT) is currently considered Fairly Valued. The stock's GF Value™ is NZ$4.18, compared to a current price of NZ$3.91 — trading 6.5% below its estimated fair value. The current Gross Margin % is 42.69%, which is near median its 10-year median of 44.09 and 12.1% below the Drug Manufacturers industry median of 48.54. AFT Pharmaceuticals' overall GF Score™ is 95/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For AFT Pharmaceuticals (NZSE:AFT), the current Gross Margin % is 42.69% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AFT Pharmaceuticals (NZSE:AFT) Overvalued in 2026?
Based on GuruFocus' analysis, AFT Pharmaceuticals stock appears to be undervalued.
The current stock price of NZ$3.91 is trading 6.5% below its estimated GF Value™ of NZ$4.18.
GuruFocus considers AFT Pharmaceuticals to be Fairly Valued.
Key valuation signals for NZSE:AFT:
Gross Margin %: 42.69% (near median its 10-year median of 44.09)
GF Value™: NZ$4.18 vs. price of NZ$3.91 (6.5% below fair value)
Industry Position: 12.1% below the Drug Manufacturers median (#570 of 943)
No single metric tells the full story. See the NZSE:AFT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AFT Pharmaceuticals Ltd is a pharmaceutical distributor and developer of pharmaceutical intellectual property. Some of the products of the organization are Maxigesic dose forms, Capsaicin creams, Crystaderm, Kiwisoothe, Micolette, and others. The group has four operating segments based on geographical location being Australia, New Zealand, Asia, and the Rest of the world. It generates the majority of the revenue from Australia, which includes the sales and distribution activity relating to the Australian market.
95GF Score
Get the complete analysis for NZSE:AFT
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NZSE:AFT has been successfully added to your 
